{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:11:38Z","timestamp":1771546298146,"version":"3.50.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Up-front autologous stem cell transplantation (ASCT) is the established standard of care for younger, transplant-eligible MCL patients and is associated with a prolonged progression-free survival (PFS) benefit. However, there is no randomized controlled trial data, with therapy including rituximab and cytarabine, that has established a PFS and overall survival (OS) benefit with ASCT in the modern era. Multiple retrospective studies have failed to identify an OS benefit associated with ASCT in younger MCL patients. The high-risk patient subgroup with evidence of baseline TP53 mutation has a dismal outcome with intensive chemoimmunotherapy followed by ASCT, thus up-front ASCT is not optimal for this patient subset. Ongoing randomized clinical trials will help to clarify the role of up-front ASCT in the future. For example, the ongoing European MCL Network Triangle study incorporating ibrutinib into chemoimmunotherapy induction and maintenance with and without ASCT will help define the role of ASCT in the era of novel biologically targeted agents (ClinicalTrials.gov identifier: NCT02858258). Additionally, minimal residual disease (MRD) assessment is a powerful prognostic tool in MCL, and the ongoing Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4151 study is comparing maintenance rituximab alone vs ASCT consolidation in MCL patients who achieve remission and MRD-undetectable status post induction (ClinicalTrials.gov identifier: NCT03267433). ASCT remains a highly efficacious initial therapy for younger MCL patients; however, ultimately the decision to pursue ASCT requires discussion of risks vs benefits, incorporating patient preferences and values.<\/jats:p>","DOI":"10.1182\/hematology.2022000333","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:08:28Z","timestamp":1670602108000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?"],"prefix":"10.1182","volume":"2022","author":[{"given":"Anita","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"11","key":"2022121313383424800_hem2022000333C1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae insights: B-cell lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"2022121313383424800_hem2022000333C2","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","volume":"56","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 4","key":"2022121313383424800_hem2022000333C3","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"2022121313383424800_hem2022000333C4","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1097\/HS9.0000000000000464","article-title":"EHA endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma","volume":"4","author":"Linton","year":"2020","journal-title":"Hemasphere"},{"issue":"7","key":"2022121313383424800_hem2022000333C5","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2022121313383424800_hem2022000333C6","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10044","key":"2022121313383424800_hem2022000333C7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"2022121313383424800_hem2022000333C8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2022121313383424800_hem2022000333C9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2021-150181","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a long-term follow-up of the randomized, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"138","author":"Hermine","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2022121313383424800_hem2022000333C10","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2022121313383424800_hem2022000333C11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2022121313383424800_hem2022000333C12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2022121313383424800_hem2022000333C13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab- high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2022121313383424800_hem2022000333C14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2022121313383424800_hem2022000333C15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2022121313383424800_hem2022000333C16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bjh.16714","article-title":"Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma","volume":"192","author":"Massaro","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"2022121313383424800_hem2022000333C17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"2022121313383424800_hem2022000333C18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","article-title":"Blastoid mantle cell lymphoma","volume":"34","author":"Jain","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"29","key":"2022121313383424800_hem2022000333C19","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313383424800_hem2022000333C20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10121","key":"2022121313383424800_hem2022000333C21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"2022121313383424800_hem2022000333C22","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2022121313383424800_hem2022000333C23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2022121313383424800_hem2022000333C24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2022121313383424800_hem2022000333C25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts [published online 28 June 2022]","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022121313383424800_hem2022000333C26","doi-asserted-by":"crossref","first-page":"911.e1","DOI":"10.1016\/j.jtct.2021.08.014","article-title":"Outcomes and utilization trends of front-line autologous hematopoietic cell transplantation for mantle cell lymphoma","volume":"27","author":"Riedell","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2022121313383424800_hem2022000333C27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10428194.2021.1978085","article-title":"The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma","volume":"63","author":"Sawalha","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2022121313383424800_hem2022000333C28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313383424800_hem2022000333C29","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/bloodadvances.2020003645","article-title":"Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival","volume":"5","author":"Glimelius","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2022121313383424800_hem2022000333C30","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2022121313383424800_hem2022000333C31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2021.279037","article-title":"Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen\u2014a real world study on patients diagnosed in Sweden 2007-2017","volume":"107","author":"Albertsson-Lindblad","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"2022121313383424800_hem2022000333C32","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bbmt.2013.07.005","article-title":"Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation","volume":"19","author":"Cassaday","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2022121313383424800_hem2022000333C33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"2022121313383424800_hem2022000333C34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2022121313383424800_hem2022000333C35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2022121313383424800_hem2022000333C36","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.17023","article-title":"p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma","volume":"191","author":"Rodrigues","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2022121313383424800_hem2022000333C37","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"2022121313383424800_hem2022000333C38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313383424800_hem2022000333C39","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2021-151831","article-title":"Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"2022121313383424800_hem2022000333C40","doi-asserted-by":"crossref","first-page":"JCO2102370","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study [published online 4 June 2022]","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"2022121313383424800_hem2022000333C41","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2022121313383424800_hem2022000333C42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.hoc.2020.06.006","article-title":"Minimal residual disease in mantle cell lymphoma: methods and clinical significance","volume":"34","author":"Ladetto","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"16","key":"2022121313383424800_hem2022000333C43","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2022121313383424800_hem2022000333C44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"2022121313383424800_hem2022000333C45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","article-title":"Ibrutinib- rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2022121313383424800_hem2022000333C46","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2019-127863","article-title":"Triangle: autologous transplantation after a rituximab\/ibrutinib\/ara-c containing induction in generalized mantle cell lymphoma\u2014a randomized European MCL Network trial","volume":"134","author":"Dreyling","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2022121313383424800_hem2022000333C47","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","article-title":"Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"20","author":"Dahi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2022121313383424800_hem2022000333C48","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 15","key":"2022121313383424800_hem2022000333C49","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2021.39.15_suppl.7503","article-title":"ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R)\u200a\u00b1\u200alenalidomide (L) consolidation for Mantle cell lymphoma: effect of adding bortezomib to front-line BR induction on PFS","volume":"39","author":"Smith","year":"2021","journal-title":"JCO"},{"issue":"26","key":"2022121313383424800_hem2022000333C50","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/155\/2023112\/155kumar.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/155\/2023112\/155kumar.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T19:14:10Z","timestamp":1701544450000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/155\/493498\/What-is-the-role-of-up-front-autologous-stem-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000333","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}